Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Interleukin 4 plasma levels in psoriasis vulgaris patients.

Authors: Zalewska, A  Wyczolkowska, J  Dziankowska-Bartkowiak, B  Sysa-Jedrzejowska, A 
Citation: Zalewska A, etal., Med Sci Monit. 2004 Apr;10(4):CR156-62.
Pubmed: (View Article at PubMed) PMID:15039646

BACKGROUND: Psoriasis is regarded as a Th1-cell type disease. Interleukin-4, a Th2 type cytokine, is diminished in psoriatic skin. It has been postulated that switching the cytokine profile from Th1 to Th2 may be of great help in the treatment of psoriasis. Some recent reports demonstrate a favorable role of IL-4 in the treatment of psoriasis. Therefore we decided to evaluate how IL-4 plasma levels fluctuate in the case of favorable treatment outcome observed in patients with clinically active and stable disease. MATERIAL/METHODS: 17 patients with active psoriasis vulgaris, 17 with stable disease, and 22 age- and sex-matched healthy controls were included in the study. IL- 4 plasma levels were evaluated by the ELISA method twice--before treatment implementation and 4 weeks thereafter. RESULTS: We observed statistically significant higher IL-4 plasma levels in the active psoriasis group both before treatment implementation (1st examination) and after 4 weeks of treatment (2nd examination) compared with both the control group (p<0.001) and the stable psoriasis group (1st examination: p<0.001, 2nd examination: p<0.01). There was no statistically significant difference in IL-4 plasma levels between the stable psoriasis and control groups in both examinations (p>0.05). CONCLUSIONS: Our data seem to support the hypothesis of the existence of immunologically distinct psoriasis subtypes.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
RGD Object Information
RGD ID: 7829812
Created: 2014-01-24
Species: All species
Last Modified: 2014-01-24
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.